Alzheimer's disease (AD) is the most common neurodegenerative disease in the developed
world. The increasing life expectancy in the last years has led to an increase in the …

Alzheimer's disease (AD) is an age-related neurodegenerative disease that affects
approximately 4.5 million people in the United States. The mainstays of current …

It is now almost a century ago that Alois Alzheimer first presented his results in public. Main
characteristics of Alzheimer's disease (AD) are massive cerebral accumulation of amyloid …

Diseases of the ageing population, such as Alzheimer's disease, could soon be viewed with
greater dread than other diseases, such as cancer. Unfortunately, although there is a wealth …

Globally, there are approximately 47 million people living with dementia, and about two
thirds of those have Alzheimer's disease (AD). Age is the single biggest risk factor for the …

Copyright of individual chapters belongs to the respective authors. The authors grant
unrestricted publishing and distribution rights to the publisher. The electronic versions of the …

Novel agents addressing non-amyloid, non-tau targets in Alzheimer's Disease (AD)
comprise 70% of the AD drug development pipeline of agents currently in clinical trials. Most …

A cascade of pathophysiological events is triggered in Alzheimer disease (AD) that
ultimately involves common cellular signaling pathways and leads to cellular and network …

Alzheimer's disease (AD) is one of the most common multifactorial diseases, including a
range of abnormal cellular/molecular processes occurring in different regions of the brain …

Human diseases involving protein misfolding and aggregation have received increasing
attention in recent years. Alzheimer's disease and other diseases associated with aging are …